InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,529.56
(
-1.05%
)
US TECH 100
19,147.59
(
-0.64%
)
Dow Jones
40,650.17
(
-1.33%
)
Brent Oil
84.04
(
-0.53%
)
Bitcoin
63,504.58
(
-0.91%
)

Replies to post #57143 on Ariad Pharmaceuticals Inc fka ARIA

Replies to #57143 on Ariad Pharmaceuticals Inc fka ARIA
icon url

lax20m

12/09/14 9:50 AM

#57145 RE: biotech_researcher #57143

It's not finished. That's not a fact that's your opinion. Iclusig certainly will play an important role in late stage cml or in patients with mutation. Tell me why it won't. Support your assertions
icon url

rurik

12/09/14 9:57 AM

#57147 RE: biotech_researcher #57143

br - You are wrong again. Ponatinib will the go to drug for all the 2nd line failures for years to come.